drug
dexamethasone
Marketedupdated 6mo agoby Fera Pharmaceuticals LLC
Approvedcommunity read0 votes
indications
investigational
Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma
all catalysts(10)
phase 0 trial completion · 1
phase 2 completion · 7
Apr 25, 2026
phase 2 completion
Nizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 25, 2026
phase 2 completion
Assiut University — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 27, 2026
phase 2 completion
BC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 28, 2026
phase 2 completion
West China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Buddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Dalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)
dexamethasone
→
phase 2 initiation · 1
Trials studying dexamethasone
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase4Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
- phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 18, 2037
~11.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 18, 2037formulationUS 10537585
- Dec 18, 2037formulationUS 11304961
FDA exclusivities (1)
- Oct 3, 2026ODE-271Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that